Ionis Announces GSK Has Advanced Bepirovirsen Into Phase 3 Development

CARLSBAD, Calif., Feb. 1, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK has initiated two randomized, double-blind, placebo-controlled Phase 3 studies evaluating the safety and efficacy of bepirovirsen...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials